NewGenIvf Group Limited Announces Pricing of $2.5 Million Underwritten Offering
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NewGenIvf Group (Nasdaq: NIVF) priced a firm commitment underwritten offering with expected gross proceeds of approximately $2.5 million before fees and expenses.
The offering covers 71,428,570 Class A ordinary shares or pre-funded warrants in their place. Shares are priced at $0.035 per share; the immediately exercisable warrants cost $0.03499 each, with a $0.00001 exercise price. The company expects the offering to close on or about November 20, 2026, subject to customary closing conditions. It expects to use the net proceeds, together with existing cash, for working capital and general corporate purposes.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Firm commitment underwritten offering is expected to raise approximately $2.5 million in gross proceeds, with closing expected on or about November 20, 2026 9.2× market cap
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.71,428,570 Class A ordinary shares or pre-funded warrants in their place would dilute existing holders; shares cost $0.035 and warrants cost $0.03499 with a $0.00001 exercise price
- Minor point. Forward-looking: it has not happened yet and may not happen.Underwriting fees and other offering expenses payable by NewGenIvf Group will reduce net proceeds
Details
Market move: NIVF -59.71% vs previous close. $2.5 million underwritten offering
On Nov 19, the day this news came out, the latest delayed price for NIVF is 59.71% below the previous close. Argus tracked a trough of -75.4% from its starting point during tracking. Our momentum scanner has recorded 46 alerts for this stock so far that day. The latest delayed price is $0.07. Relative volume is exceptionally heavy at 17.6x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Expected gross proceeds
- Approximately $2.5 million
- Before underwriting fees and other offering expenses
- Offering securities
- 71,428,570 Class A ordinary shares
- Pre-funded warrants may be issued in lieu of shares
- Ordinary share price
- $0.035 per share
- Offering price
- Pre-funded warrant price
- $0.03499 per warrant
- Offering price
- Warrant exercise price
- $0.00001 per warrant
- Pre-funded warrants
- Expected closing
- On or about November 20, 2026
- Subject to customary closing conditions
Previous Offering Reports
-
Closed a public offering, raising approximately $1.25 million in gross proceeds.
-
Priced a public offering expected to raise approximately $1.25 million in gross proceeds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
firm commitment financial
underwritten offering financial
pre-funded warrants financial
shelf registration statement regulatory
form f-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BANGKOK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a technology-driven, diversified growth company, today announced the pricing of a firm commitment underwritten offering with gross proceeds to the Company expected to be approximately
The offering consists of 71,428,570 Class A Ordinary Shares (or Pre-Funded Warrants in lieu thereof). The offering price per Class A Ordinary Share is
Aggregate gross proceeds to the Company are expected to be approximately
Aegis Capital Corp. is acting as the sole book-running manager for the offering. Han Kun Law Offices LLP is acting as U.S. counsel to the Company. Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp.
The offering is being made pursuant to an effective shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.
Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NewGenIvf Group Limited
NewGenIvf Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.